Mitsubishi UFJ Trust & Banking Corp Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Mitsubishi UFJ Trust & Banking Corp lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 22.5% in the second quarter, HoldingsChannel.com reports. The firm owned 85,734 shares of the biopharmaceutical company’s stock after selling 24,931 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Alnylam Pharmaceuticals were worth $27,957,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $243,000. Envestnet Asset Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 9.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 72,047 shares of the biopharmaceutical company’s stock worth $19,454,000 after acquiring an additional 6,033 shares in the last quarter. Cerity Partners LLC lifted its stake in Alnylam Pharmaceuticals by 8.3% during the first quarter. Cerity Partners LLC now owns 14,642 shares of the biopharmaceutical company’s stock worth $3,953,000 after purchasing an additional 1,117 shares during the last quarter. Mutual of America Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 673.9% in the first quarter. Mutual of America Capital Management LLC now owns 13,644 shares of the biopharmaceutical company’s stock valued at $3,684,000 after purchasing an additional 11,881 shares in the last quarter. Finally, CWM LLC increased its stake in Alnylam Pharmaceuticals by 26.3% in the first quarter. CWM LLC now owns 16,664 shares of the biopharmaceutical company’s stock valued at $4,500,000 after purchasing an additional 3,473 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on ALNY shares. Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research note on Monday, October 6th. Oppenheimer reiterated an “outperform” rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Wolfe Research raised Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research report on Monday, August 4th. Citigroup raised their price target on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the company an “equal weight” rating in a research note on Tuesday. Twenty-three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $482.17.

Alnylam Pharmaceuticals Stock Up 0.3%

ALNY opened at $453.97 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The business has a 50 day moving average price of $458.86 and a two-hundred day moving average price of $381.74. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The company has a market cap of $59.98 billion, a PE ratio of -183.79 and a beta of 0.30.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,103,454.05. Following the transaction, the executive vice president directly owned 25,231 shares of the company’s stock, valued at approximately $11,405,673.55. The trade was a 8.82% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Pushkal Garg sold 3,022 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the transaction, the executive vice president owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. The trade was a 13.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 66,696 shares of company stock valued at $30,430,694. Corporate insiders own 1.20% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.